Cargando…

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

OBJECTIVE: The mainstay treatment of esophageal squamous cell carcinoma (ESCC) involves chemotherapy and immunotherapy. However, alternative therapies are required for patients who are refractory or intolerant to existing therapies. METHODS: In this single-arm, multicenter, open-label phase Ib study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Ming, Wang, Meng, Deng, Ting, Bai, Yuxian, Zang, Kai, Miao, Zhanhui, Gai, Wenlin, Xie, Liangzhi, Ba, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958882/ https://www.ncbi.nlm.nih.gov/pubmed/35014769 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0388

Ejemplares similares

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting
por: Zhou, Yi-Xin, et al.
Publicado: (2021)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

SCT Barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

SCT barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

Commissioning of the SCT
por: Hayward, H
Publicado: (2008)

Observation of second sound in graphite over 200 K
por: Ding, Zhiwei, et al.
Publicado: (2022)

Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
por: Li, Yan, et al.
Publicado: (2022)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Redundancy and Synchronisation in the SCT
por: Nickerson, R B, et al.
Publicado: (1996)

Redundancy and Synchronisation in the SCT
por: Nickerson, R B, et al.
Publicado: (1996)

Status of the ATLAS SCT
por: Clark, Allan, et al.
Publicado: (2007)

ATLAS SCT Commissioning
por: Limper, Maaike
Publicado: (2007)

A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma
por: Jaffe, Dena H., et al.
Publicado: (2022)

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
por: Xu, Jianming, et al.
Publicado: (2022)

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
por: Fukuoka, Shota, et al.
Publicado: (2016)

The hatfield SCT lunar atlas: photographic atlas for Meade, Celestron and other SCT telescopes
por: Cook, Jeremy
Publicado: (2005)

The Hatfield SCT lunar atlas: photographic atlas for Meade, Celestron, and other SCT telescopes
por: Cook, Anthony
Publicado: (2014)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Yang, Fan, et al.
Publicado: (2021)

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
por: Song, Zhengbo, et al.
Publicado: (2014)

SCT - Semi-Conductor Tracker
por: Vanden Broeck, Renilde
Publicado: (2019)

Determination of SCT Wheel Positions
por: Haywood, S
Publicado: (2001)

Module Overlaps in the SCT and Pixels
por: Haywood, S
Publicado: (2002)

The ATLAS SCT Production Database
por: Clark, A, et al.
Publicado: (2002)

Performance of VCSELs for SCT links
por: Mandic, I, et al.
Publicado: (1998)

Comments on "the Forward SCT Layout"
por: Clark, Allan G, et al.
Publicado: (1999)

Optical links for the ATLAS SCT
por: Beringer, J, et al.
Publicado: (1997)

SCT review. Inner deector
por: Tyndel, M
Publicado: (1996)

Optimization of the forward SCT layout
por: Clark, A, et al.
Publicado: (1995)

ATLAS SCT hybrid experience
por: Unno, Yoshinobu
Publicado: (2005)

The ATLAS semiconductor tracker (SCT)
por: Jackson, J N
Publicado: (2005)

SCT Endcap Geometry and Surveys
por: Foster, J M, et al.
Publicado: (2007)

LncRNA BC200 Promotes Esophageal Squamous Cell Cancer Migration and Invasion and Can Regulate ATF4 Expression
por: Zhao, Ruihua, et al.
Publicado: (2020)

Coexpression of periostin and EGFR in patients with esophageal squamous cell carcinoma and their prognostic significance
por: Jia, Wei, et al.
Publicado: (2016)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis
por: Müller, Moritz, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tkd647e2pjh5o1elf0ita6ai75